Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)

Merry Christmas from Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)!   Wishing you a joyful holiday season filled with health, happiness, and exciting advancements for the year ahead.

Ibezapolstat: Transforming the Treatment of C. difficile Infection (#CDI)   #C. difficile infection impacts nearly 500,000 people in the U.S. annually, with many facing severe complications and recurrence.    Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)' lead candidate, #Ibezapolstat, offers a novel approach to addressing this critical health issue.   With its innovative mechanism as a DNA polymerase IIIC inhibitor, Ibezapolstat targets CDI effectively while preserving gut microbiome health.    Backed by promising clinical trial results and FDA designations like QIDP and Fast Track status, it is advancing toward Phase 3 trials with the potential to reshape CDI treatment.   Learn more at www.acurxpharma.com

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is thrilled to announce our participation in The Microcap Conference, taking place January 28-30, 2025, at the Borgata Hotel in Atlantic City, New Jersey. I will be presenting on Acurx Pharmaceuticals' innovative work in developing a new class of antibiotics to tackle difficult-to-treat bacterial infections. Presentation Details:  Date: Wednesday, January 29th  Time: 10:00 AM ET  Looking forward to connecting: https://lnkd.in/evQgR-Ue #AcurxPharmaceuticals #AntibioticInnovation #InfectiousDiseases #HealthcareLeadership #MicrocapConference #HealthcareInnovation #ACXP

#ACXP #Antibiotics #Acurx #Pharma #ClinicalTrials  Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is excited to announce significant progress in preparing for Phase 3 trials of ibezapolstat. We are a late-stage biopharmaceutical company developing a new class of antibiotics for bacterial infections. With positive FDA feedback on our CMC plan and active discussions with the EMA, we are advancing our international Phase 3 trial planning, including efforts in Japan, Canada, and the UK. As always, we remain committed to addressing the global challenge of C. difficile Infection and antibiotic resistance. https://lnkd.in/evDYerpV #ACXP #Antibiotics #Acurx #Pharma #ClinicalTrials 

Why Congress must help in the fight against superbugs and facilitate development of antimicrobials to fight them   Antibiotic resistance contributes to roughly 170,000 U.S. deaths annually, and the toll grows each year.   According to a new analysis, antibiotic resistance is forecast to cause more than 39 million global deaths between 2025 and 2050.   Alarmingly, these pathogens are evolving to resist even our strongest antimicrobials. Soon, we may not have any way of combating these infections — unless biopharmaceutical companies are able to develop new medicines. To do so, those companies will need some help from Congress.   https://lnkd.in/eXu5HXjP   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) remains dedicated to addressing this crisis by developing a new class of antibiotics for difficult-to-treat bacterial infections. As the fight against AMR continues, sustainable solutions are more critical than ever.   #AntibioticResistance #AMR #GlobalHealth #Nasdaq #AcurxPharma #InnovationInHealthcare

3 Ways the New Administration Could Speed the Path to New Medicines   Most importantly, pass the Pasteur Act.    https://lnkd.in/eg2Wa6jf   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) remains dedicated to addressing this crisis by developing a new class of antibiotics for difficult-to-treat bacterial infections. As the fight against AMR continues, sustainable solutions are more critical than ever.   #AntibioticResistance #AMR #GlobalHealth #Nasdaq #AcurxPharma #InnovationInHealthcare

Happy Thanksgiving from Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)

The Superbug Fight Needs a Better Business Model Antimicrobial resistance (AMR) is already a leading global cause of death, surpassing diseases like HIV, malaria, and tuberculosis. Without urgent action, superbugs could claim 39 million lives by 2050 and cost $855 billion annually in healthcare expenses and lost productivity. Yet, the pipeline for new antibiotics is shrinking. With antibiotic makers struggling to stay afloat, small biotech companies are shouldering the burden as Big Pharma exits the space. The current business model—where novel antibiotics are saved for emergencies—may work for public health but leaves companies without the revenue to survive. Innovative solutions, like “push” and “pull” incentives, aim to revitalize the antibiotic pipeline. These mechanisms reduce financial risks for developers while ensuring lifesaving drugs reach those who need them most. But without immediate investment and global cooperation, the collapse of antibiotic innovation is imminent. https://lnkd.in/ebGgEpNw Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) remains dedicated to addressing this crisis by developing a new class of antibiotics for difficult-to-treat bacterial infections. As the fight against AMR continues, sustainable solutions are more critical than ever. #AntibioticResistance #AMR #GlobalHealth #Nasdaq #AcurxPharma #InnovationInHealthcare

‘It is a pandemic’: UK’s envoy on superbugs says scale of threat underestimated   Dame Sally Davies says action on deadly antibiotic-resistant infections must be prioritised   The rising death toll from drug-resistant bugs is “very scary” and people do not even realise it is happening, the UK’s special envoy for antimicrobial resistance (AMR) has said.   By 2050 it is projected that drug-resistant bugs will kill nearly 2 million people each year and play a role in the deaths of 8 million people. The figures put AMR in a similar ballpark to the Covid-19 pandemic, which the World Health Organization (WHO) estimates led to 4m excess deaths in 2020 and 10m in 2021.   https://lnkd.in/eBtUMh5w   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is a late-stage biopharmaceutical company dedicated to developing a new class of antibiotics for difficult-to-treat bacterial infections like C. difficile.   #AntibioticResistance #AMR #Globalhealth #Nasdaq #ACXP